BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 17, 2025
See today's BioWorld
Home
» OGS Gains European Approval, Partner For Gaucher's Product
To read the full story,
subscribe
or
sign in
.
OGS Gains European Approval, Partner For Gaucher's Product
July 29, 2002
By
Nuala Moran
No Comments
LONDON - Oxford GlycoSciences plc said Friday it received approval in Europe for Vevesca, an oral treatment for Gaucher's disease that was turned down by the FDA on June 24. (BioWorld Today)
BioWorld
